ClinicalTrials.Veeva

Menu
S

Southern Adelaide Local Health Network | Southern Adelaide Diabetes and Endocrine Services

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BI 3034701
Maridebart Cafraglutide
Fenofibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 5 total trials

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes (Enith2)

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropi...

Enrolling
Obesity or Overweight
Type 2 Diabetes Mellitus
Combination Product: Enicepatide
Combination Product: Placebo

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropi...

Enrolling
Obesity or Overweight
Combination Product: Enicepatide
Combination Product: Placebo

This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more an...

Enrolling
Overweight
Obesity
Drug: Placebo matching BI 3034701
Drug: BI 3034701

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Active, not recruiting
Obesity
Drug: Placebo
Drug: Maridebart Cafraglutide

The purpose of this study is to evaluate the potential benefits of 145 mg of daily fenofibrate in adults with type 1 diabetes mellitus and pre-existi...

Active, not recruiting
Diabetic Nephropathies
Type 1 Diabetes Mellitus
Drug: Inert lactose placebo
Drug: Fenofibrate

Trial sponsors

Roche logo
Amgen logo
Boehringer Ingelheim logo
U

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems